Finance

Lists
Why is CNMD down 2.42%?
Dive Deeper
CNMD:NYSE
Conmed Corp
$46.83
-2.42%
(-1.16) 1D
Nov 19, 3:15:20 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CNMD...
Open
$48.40
High
$48.40
Low
$45.31
Mkt. cap
1.40B
Avg. vol.
400.60K
Volume
245.23K
P/E ratio
19.42
52-wk high
$54.80
52-wk low
$31.44
EPS
$2.41
Beta
0.90
Shares outstanding
29.80M
No. of employees
4K
Open
$48.40
High
$48.40
Low
$45.31
Mkt. cap
1.40B
Avg. vol.
400.60K
Volume
245.23K
P/E ratio
19.42
52-wk high
$54.80
52-wk low
$31.44
EPS
$2.41
Beta
0.90
Shares outstanding
29.80M
No. of employees
4K
News stories
From web sources and news partners
About Conmed Corp
CEOCurt R. Hartman
Employees3.9K
Founded1970
HeadquartersLargo, Florida, United States
SectorHealth Care
IndustryMedical device
Websiteconmed.com
Analyst ratings
Based on 5 analysts giving stock ratings to CNMD in the past 3 months
Hold
Buy
0
Hold
5
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CNMD in the last 3 months.
Highest
Current $46.83
$50.00 (+6.77%)
Average
$47.25 (+0.90%)
Lowest
$45.00 (-3.91%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew O'Brien
Piper Sandler
Hold
Reiterated
$45.00
-3.9%
11/13/2026
Robbie Marcus
J.P. Morgan
Hold
Maintained
$50.00
+6.8%
10/29/2026
Vik Chopra
BMO Capital
Hold
Maintained
$45.00
-3.9%
10/28/2026
Michael Matson
Needham
Hold
Maintained
-
-
10/29/2026
Larry Biegelsen
Wells Fargo
Hold
Reiterated
$49.00
+4.6%
10/29/2026
Travis Steed
Bank of America Securities
Sell
Maintained
-
-
07/30/2026
Unknown Analyst
BMO Capital
Hold
Initiated
$36.00
-23.1%
07/09/2026
Last report
Oct 28, 2026
Fiscal period
Q3 2026
$1.04 / $1.00
+3.74%beat
Revenue / Est. (USD)
335.56M / 336.25M
-0.21%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
373.20M
317.05M
343.49M
335.56M
Cost of goods sold
184.51M
133.60M
139.13M
154.91M
Cost of revenue
184.51M
133.60M
139.13M
154.91M
Research and development expenses
14.90M
16.33M
15.50M
15.59M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
134.42M
133.48M
138.57M
132.71M
Operating expense
149.31M
149.81M
154.07M
148.30M
Total operating expenses
333.83M
283.41M
293.20M
303.21M
Operating income
39.37M
33.64M
50.29M
32.35M
Other non operating income
-363.00K
-
2.82M
-
EBT including unusual items
29.25M
18.36M
31.35M
26.01M
EBT excluding unusual items
31.64M
26.58M
45.23M
21.21M
Income tax expense
12.51M
4.53M
8.28M
6.21M
Effective tax rate
42.78%
24.66%
26.40%
23.89%
Other operating expenses
-
-
-
-
Net income
16.74M
13.83M
23.07M
19.80M
Net profit margin
4.49%
4.36%
6.72%
5.90%
Earnings per share
1.43
0.89
1.38
1.04
Interest and investment income
-
-
-
-
Interest expense
-7.37M
-7.06M
-7.88M
-11.14M
Net interest expenses
-7.37M
-7.06M
-7.88M
-11.14M
Depreciation and amortization charges
-
-
-
-
EBITDA
57.02M
52.47M
69.34M
51.53M
Gain or loss from assets sale
-
-3.92M
2.40M
-312.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps